Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

OGT Launches High-Resolution, High-throughput PGS Array

Published: Wednesday, July 09, 2014
Last Updated: Wednesday, July 09, 2014
Bookmark and Share
Confident genome-wide aneuploidy detection in 14 samples on a single array.

Oxford Gene Technology (OGT) has announced the launch of a new high-resolution, high-throughput pre-implantation genetic screening (PGS) microarray aimed at improving embryo screening for in vitro fertilization (IVF).

The CytoSure™ Embryo Screen Array offers eight arrays of 60,000 spots for high-resolution genome-wide aneuploidy and copy number detection in pre-implantation embryos.

The microarray can screen up to 14 embryos on a single slide, which is particularly useful in embryo banking - a common procedure for advanced maternal age samples - enabling the confident identification of the best embryo for implantation.

The CytoSure Embryo Screen Array is sensitive enough to work with small amounts of amplified DNA from a single embryo cell. For optimal hybridization and maximum accuracy, the probe design of the CytoSure array exactly mirrors only the amplified DNA; regions of the genome that have not been amplified are therefore not represented, minimizing the possibility of misleading results.

Oligonucleotide arrays, such as the CytoSure Embryo Screen Array, typically provide lower batch-to-batch variation than alternative bacterial artificial chromosome (BAC) arrays, enabling more reliable analysis. In addition, flexibility in design and content further enhances the ability of oligonucleotide arrays to meet future research requirements.

The CytoSure Embryo Screen Array has been research-validated by the team at the Center for Human Genetics, University Hospital Leuven, Belgium. In the lab of Professor Joris Vermeesch they found that “the CytoSure array offers a good alternative to FISH or BAC aCGH for the detection of aneuploidies and chromosomal imbalances in DNA amplified from single embryo cells”.

“With an estimated 250,000 PGS tests performed each year worldwide and growing at a rate of over 10% per annum,” said Dr Mike Evans, CEO, OGT, “we saw a clear and unmet need for our optimized, oligo-based aCGH CytoSure Embryo Screen array. It offers significant advances over alternative platforms, including the facility to analyze up to 14 samples on a single array. This new array continues our goal of helping potential parents maximize their chances of IVF success.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OGT Announces Commercial and Financial Highlights for FY 2015
New products launched across all core brands; Cytocell® FISH, SureSeq™ NGS and CytoSure™ arrays for cancer and rare disease.
Saturday, December 12, 2015
OGT Licenses SNP Probe Technology to BMGL
Proprietary technology allows superior LOH detection in challenging samples.
Friday, November 13, 2015
OGT’s Popular ESHG Workshop Free to View Online
Learn about the next generation of microarrays in one of the best attended workshops of the conference.
Friday, July 17, 2015
OGT Signs License with Wellcome Trust Sanger Institute
OGT will use novel data on developmental disorders to advance microarray and NGS products for accurate and cost effective identification of rare diseases.
Saturday, April 04, 2015
Oxford Gene Technology Awarded £1.2m Genomics England Contract
Next Generation Sequencing analysis software will support 100,000 Genomes Project by providing intuitive reports for clinical interpretation.
Monday, March 16, 2015
OGT Announces Operational and Financial Highlights for FY 2014
OGT’s molecular genetics business delivers 54% growth in commercial revenues to £11.9m.
Tuesday, December 09, 2014
Pieces of the Puzzle - A Multi-method Approach to Tumour Profiling
OGT workshop provides insight on using complementary genomic technologies.
Friday, November 07, 2014
An Integrated Approach to Clinical Genetics Research
OGT’s new whitepaper explores the next stage of molecular testing.
Wednesday, April 09, 2014
OGT Announces Acquisition of Cytocell Ltd
Company expands leadership in genomic medicine.
Thursday, March 06, 2014
Oxford Gene Technology Expands Leadership in Genomic Medicine
The Company today announced the acquisition of Cambridge-based Cytocell Limited.
Tuesday, March 04, 2014
OGT Strengthens Focus on Cancer Biomarkers
Oxford Gene Technology announce the appointment of Dr Bob Holland as Chief Medical Officer.
Monday, October 21, 2013
OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
OGT Awarded Best Medtech Dealmaker by Oxford Bioscience Network
Award recognizes OGT’s collaboration with Birmingham and Salisbury NHS Regional Genetics Laboratories.
Wednesday, October 09, 2013
Exploring the Next Generation of Cancer Genomics at BSGM
aCGH to NGS: OGT invites University of Oxford Professor to present latest research.
Thursday, September 12, 2013
New Whitepaper Compares Targeted Resequencing Strategies
OGT provides insight into choice of NGS methods.
Wednesday, July 17, 2013
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Ovarian Cancer Insight
Study showed tumours release cytokines to attract macrophages, which secrete growth factors that in turn promote tumour growth.
Questioning the Safety of Selenium to Combat Cancer
Research indicates the need for change in practice as selenium supplements cannot be recommended for preventing colorectal cancer.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Leukaemia Cell Movement Gives Clues to Tackling Treatment-Resistant Disease
Researchers at Imperial College London have suggested that the act of moving itself may help the cells to survive, possibly through short-lived interactions with an array of our own cells.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos